Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Sibylle Haemmerle, Swapnil Dahale et al.|Journal of Allergy and Clinical Immunology|2023Cited by 71